Kim Jae Hyuk, Kim Hyun Joon, Kim Sun Woong
Department of Ophthalmology, Wonju Severance Christian Hospital, Wonju, South Korea.
BMC Ophthalmol. 2019 Jul 24;19(1):158. doi: 10.1186/s12886-019-1166-2.
To report the first case of allergic contact dermatitis (ACD) associated with alcaftadine 0.25% ophthalmic solution.
The patient was a 51-year-old woman with no previous history of side effects to ophthalmic antihistamine agents. She had been prescribed alcaftadine 0.25% for allergic conjunctivitis. On first application of the medication, she did not experience any cutaneous reaction. One day later, after the second alcaftadine 0.25% application, both eyelids became swollen, and erythematous changes were evident. On slit-lamp examination, conjunctival injection was noted in the absence of conjunctival swelling or any other findings. Fundus examination was unremarkable. To evaluate the cause of ACD, a patch test was performed and 48 h later was noted to be positive for alcaftadine 0.25%. Based on the positive patch test, the patient was diagnosed with ACD caused by alcaftadine 0.25%. After 9 days of treatment, the swelling and erythema completely resolved.
Although there have been no previous reports of alcaftadine 0.25%-associated ACD, it should be suspected in patients with swelling and erythematous change of both eyes after using alcaftadine 0.25%.
报告首例与0.25%阿伐斯汀眼药水相关的过敏性接触性皮炎（ACD）病例。
患者为一名51岁女性，既往无眼部抗组胺药副作用史。她因过敏性结膜炎被处方使用0.25%阿伐斯汀。首次用药时，她未出现任何皮肤反应。一天后，在第二次使用0.25%阿伐斯汀后，双眼睑肿胀，红斑变化明显。裂隙灯检查发现结膜充血，无结膜肿胀或其他任何异常。眼底检查无异常。为评估ACD的病因，进行了斑贴试验，48小时后发现对0.25%阿伐斯汀呈阳性。基于斑贴试验阳性，患者被诊断为0.25%阿伐斯汀引起的ACD。经过9天治疗，肿胀和红斑完全消退。
尽管此前尚无0.25%阿伐斯汀相关ACD的报道，但在使用0.25%阿伐斯汀后出现双眼肿胀和红斑变化的患者中应怀疑该病。
